...
首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing.
【24h】

Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing.

机译:T细胞淋巴瘤细胞中肿瘤抑制基因的多基因表观遗传沉默;沉默后p16蛋白的表达延迟。

获取原文
获取原文并翻译 | 示例
           

摘要

To understand better T-cell lymphomagenesis, we examined promoter CpG methylation and mRNA expression of closely related genes encoding p16, p15, and p14 tumor suppressor genes in cultured malignant T-cells that were derived from cutaneous, adult type, and anaplastic lymphoma kinase (ALK)-expressing T-cell lymphomas. p16 gene was epigenetically silenced in all but one of the 10 malignant T-cell lines examined, p15 gene silenced in roughly half of the lines, and p14 was the least frequently affected. Extensive methylation of the p16 promoter was seen in six out of 10 cutaneous T-cell lymphoma patient samples and corresponded with lack of p16 protein expression in the cases examined. Treatment of cultured T-cells with the DNA methyltransferase inhibitor, 5-aza-2-deoxy-cytidine, resulted in reversal of the p16 gene silencing. However, expression of p16 protein was delayed in relationship to p16 promoter demethylation and required up to 3 weeks to occur, seemingly reflecting late activation of the p16 gene. These findings indicate that epigenetic silencing affects in T-cell malignancies, often simultaneously, several tumor suppressor genes that impact on key cell functions. The observed differential silencing of p16 and p14, and to a lesser degree p15 gene, indicates that the silencing is governed by precise, promoter region-specific mechanisms. The study provides also further rationale for treatment of at least some types of T-cell lymphomas with DNA methyltransferase inhibitors to target the epigenetically silenced tumor suppressor genes.
机译:为了更好地了解T细胞淋巴瘤的发生,我们在培养的恶性T细胞中检测了启动子CpG甲基化和密切相关的编码p16,p15和p14抑癌基因的mRNA的表达,这些恶性T细胞来源于皮肤,成年类型和间变性淋巴瘤激酶( ALK)表达的T细胞淋巴瘤。除所检查的10种恶性T细胞系之一外,p16基因在表观遗传上全部沉默,p15基因在大约一半的系中沉默,而p14受影响最少。在10个皮肤T细胞淋巴瘤患者样本中,有6个样本中发现了p16启动子的广泛甲基化,这与所检查的病例中缺乏p16蛋白表达相对应。用DNA甲基转移酶抑制剂5-氮杂-2-脱氧胞苷处理培养的T细胞可逆转p16基因沉默。但是,p16蛋白的表达与p16启动子去甲基化有关,被延迟,需要长达3周的时间才能出现,这似乎反映了p16基因的晚期激活。这些发现表明表观遗传沉默通常会同时影响几个影响关键细胞功能的抑癌基因,从而影响T细胞恶性肿瘤。观察到的p16和p14,以及较小程度的p15基因的差异沉默,表明沉默受精确的启动子区域特异性机制支配。该研究还为用DNA甲基转移酶抑制剂治疗至少某些类型的T细胞淋巴瘤提供了进一步的理论依据,以靶向表观遗传沉默的肿瘤抑制基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号